By 
American City Business Journals
Viatris keen to increase dividends
Canonsburg-based drug manufacturer Viatris Inc. said its initial return to shareholders in 2022 will come in the form of dividends, with CEO Michael Goettler not completely shutting the door on stock buybacks but saying the latter was a more complex issue. Viatris (NYSE: VTRS), which will turn a year old next week, is the combination of Mylan NV and the Upjohn unit of Pfizer Inc. (NYSE: PFE). Viatris had earnings of $311.5 million, 26 cents a share, on revenue of $4.5 billion, compared to $185.7 million, 36 cents a share, on revenue of $2.9 million for Mylan and Upjohn a year ago.
Comments